Sinphar Pharmaceutical Co. Ltd. · TWSE:1734
Sinphar Pharmaceutical — 2019 Sinphar Pharmaceutical Investor Conference
21 slides from Sinphar Pharmaceutical's conference presentation, Dec 18, 2019
Slide 1: Sinphar Pharmaceutical Investor Conference
SINPHAR’S Code: 1734 SynCore’s Code: 4192 SINPHAR PHARMACEUTICAL CO.,LTD Investor Conference 2019/12/18
Slide 2: Disclaimer
Disclaimer 本簡報是建立於本公司從各項來源所取得之資 訊。有些資訊可能受未來不確定性因素影響， 致使與原先本公司對於未來前景的說明迥異。 未來若有變更或調整時，請以公開資訊觀測站 公告資訊為依據。 This presentation is based on the information obtained from various sources which the company believes to be reliable. But at some point in the future, there are a variety of factors which cou
Slide 3: Index
Index 1. Focus Y2020 2. Group Operation 3. Important Events and Social Responsibility 3
Slide 4: Founded in Taiwan, Step Forward to The World
Founded in Taiwan, Step Forward to The World 1977 1997 2012 Established Sinphar Established CanCap Merged ZuniMed Biotech Ilan, Taiwan Vancouver, Canada Nantou,TW Generic、functional food、 Clinical control for New Drug of North Medical facilities cosmetic America、spot of international business 2002 2
Slide 5: Preventive Medicine
Preventive Medicine (tablet, hard capsule, soft capsule, granule and powder, liquid(oral), jelly candy and pastilles.) 1. Domestic Business： • Continue to develop new functional foods with currently 6 products having obtained health food certification licenses. (Delays aging, fights fatigue, improve
Slide 6: Medicine Developments
Medicine Developments (Tablet, ointment, liquid (external use), liquid(oral), eye drops, hard capsule, soft capsule, suppository, granule and injections for oncology) 1. Domestic Business： • Have run pilots on ten products (Breast Cancer, Colorectal Cancer, Lymphoma, Pancreatic Cancer, Gastric Cance
Slide 7: Sinphar Counter
Sinphar Counter 1. Strengthen direct communications with members • 30,000 customers joined as members in 2019. • In-house nutritionists sharing constant informational updates on social media FB and Line. • Personalized exclusive membership offers with above and beyond comprehensive service follow up
Slide 8: Intelligent Manufacturing
Intelligent Manufacturing NTD in Thousand 2017 Q1-Q3 2018 Q1-Q3 2019 Q1-Q3 Group Revenue 1,565,711 1,617,574 1,723,050 Ave. employee of Group 1,038 1,012 988 Ave. revenue per person 1,509 1,598 1,744 ASPROVA: Advanced scheduling system, based on resource input, equipment status to create production
Slide 9: Sustainable Management
Sustainable Management Energy Carbon Saving Reducing Annual electricity consumption Reduced CO2 emissions by decreased by 135 tons/year; Reduced total drainage by 5% approx. 30% Natural gas instead of heavy oil Reduced sludge removal by 2020Q2 Online approx. 70% Note: Compared from 2019 Jan. - Nov.
Slide 10: Group resources integration
Group resources integration Sinphar & SynCore Drugs in R & D cooperation and manufacturing improve. Sinphar & TianLi Oncology R&D achievement mutually Dosages benefit. Patents cooperation layout. Natural Medical Herbal Facilities Resources Sinphar & ZuniMed ISO15378 Class 100,000 clean room. 10
Slide 11: Research results
Research results 2019 Product Innovation Award of Plant Extract TianLife SCI papers patents granted in countries Brain Health Muscle Strengthen Enhance nutrient absorption 1. Anti-amyloid aggregation & 1. Turn on muscle protein synthesis 1. Increase absorption channels deposition genes 2. Let nutrie
Slide 12: Rapid Market Growth
® As. a4 invent roe Over Two Hundreds Billions USD Rapid Market Growth 2021 Global Functional Health Food Market (USD) 279 billion * Brain Health Market ASG RR BIR ‘S sins Compound Annual Growth Rate(CAGR) 3. 1% 2015-2017 USD 14. 2bittion(2020)- siasevamHse8% Cognition & Vitality Booster Brain Awake
Slide 13: Make a difference to push on international market
Make a difference to push on international market Functional Ingredients for living Taiwan Combine with Government's policy. Trust sense of Sinphar Brand. China To meet the Taiwan market demand One of the indispensable consumption and growth. market in Asia. Government developing an implem
Slide 14: Pipeline of New Products
Pipeline of New Products UNMET MEDICAL NEED UNMET MEDICAL NEED 14
Slide 15: Development of New Drug
Development of New Drug Indication Total market value/year From Market Research Engine, the global market value of Pancreatic Cancer will increase to US$13 billion in 2021. Pancreatic Cancer Up to 560,000 Pancreatic Cancer Patients Worldwide in 2025. (WHO IARC GLOBOCAN, (World Health Organization, I
Slide 16: EPS and Dividends
EPS and Dividends 2.50 1.8 EPS 1.6 股利 Dividends 2.00 1.4 1.2 1.50 1 0.8 1.00 0.6 0.4 0.50 0.2 0.00 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Continue making profits every year to distribute dividends regardless the economic situation, polic
Slide 17: Recent Group Revenue
Recent Group Revenue NTD in Thousand 2019/11Rev. 2,143,271 1,750,000 1,700,000 1,650,000 1,600,000 1,550,000 1,500,000 1,450,000 2017Q1-Q3 2018Q1-Q3 2019Q1-Q3 Term 2017 Q1-Q3 2018 Q1-Q3 2019 Q1-Q3 2017 Annual 2018 Annual Therapeutic 1,071,522 1,112,925 1,180,870 1,470,125 1,528,051 drug Functional 4
Slide 18: Recent Profit and Loss
Recent Profit and Loss NTD in Thousand Term 2019 Q3 2018 Q3 2018 Annual Revenue 1,723,050 1,617,367 2,215,837 Gross Profit 38% 36% 37% S&M 240,151 237,862 316,068 G&A 182,781 179,315 252,234 R&D 377,543 258,528 376,376 Profit before Tax (105,734) (69,308) (87,681) Net income (loss) (143,984) (91,419
Slide 19: 2019 Events
2019 Events • The latest research results of “How cistanche tubulosa extracts resist the accumulation of amyloid beta (Amyloid Beta)” were published in the International Molecular (Molecules, Volume 24, lssue 4 (Feb 02 2019)) and were selected as Cover article. • Signed an exclusive agency agreement
Slide 20: Corporate Social Responsibility
Corporate Social Responsibility 1. Promote social care, medical prevention and health education • Host health forum, biotechnology camp. Combined medical, academia, and biotechnology community to set up an interaction platform. Also, cultivate talented personnel. • Continually to sponsor Breast Canc
Slide 21: Q&A
Q&A • Cooperation & Development: 張智超。 (886-2-27603688 # 2304) • Investor Services: 陳淑夏。 (886-2-27603688 # 2237) 21
Sinphar Pharmaceutical — 2019 Sinphar Pharmaceutical Investor Conference on 6ix